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Abstract
Background: Controlling the growth of pharmaceutical expenditures is a major global challenge.
Promotion of generic drug prescriptions or use is gaining increased support. There are substantial
contextual differences in international experiences of implementing pharmaceutical policies related
to generic drugs. Reporting these experiences from varied perspectives can inform future policy
making. This study describes an experience of Taiwan, where patients with chronic (long-term)
conditions are usually managed in hospitals and drugs are provided in this setting with costs
reimbursed through the National Health Insurance (NHI). It investigates the effects of Taiwan's
reimbursement rate adjustment based on chemical generic grouping in 2001. This research also
demonstrates the use of micro-level longitudinal data to generate policy-relevant information. The
research can be used to improve efficiency of health care resource use.
Methods: We chose the three most-used classes of cardiovascular drugs for this investigation:
beta blocking agents, calcium channel blockers mainly with vascular effects, and plain ACE
inhibitors. For each drug class, we investigated changes in daily expense, consumption volume, and
total expenditures from a pre-action period to a corresponding post-action period. We compared
an exposure or "intervention" group of patients targeted by the action with a comparisonor
"control" group of patients not targeted by the action. The data sources are a longitudinal database
for 200,000 NHI enrolees, corresponding NHI registration data of health care facilities, and an
archive recording all historical data on the reimbursement rates of drugs covered by the NHI. We
adopted a fixed effects linear regression model to control for unobserved heterogeneity among
patient-hospital groups. Additional descriptive statistics were applied to examine whether any
inappropriate consumption of drugs in the three classes existed.
Results: The daily drug expense significantly decreased from the pre-action period to the post-
action period for the exposure group. The average magnitudes of the decreases for the three
classes of drugs mentioned above were 14.8%, 5.8% and 5.8%, respectively. In contrast, there was
no reduction for the comparison group. The number of days of the prescription increased
significantly from the pre- to the post-action period for both exposure and comparison groups. The
total expense also significantly increased for both patient groups. For the exposure group, the
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average magnitudes of the growth in the total expenditure for the three classes of drugs were
47.7%, 60.0% and 55.3%, respectively. For the comparison group, they were 91.6%, 91.6% and
63.2%, respectively. After the action, approximately 50% of patients obtained more than 180 days
of prescription drugs for a six-month period.
Conclusion: The 2001 price adjustment action, based on generic grouping, significantly reduced
the daily expense of each of the three classes of cardiovascular drugs. However, in response to this
policy change, hospitals in Taiwan tended to greatly expand the volume of drugs prescribed for
their regular patients. Consequently, the total expenditures for the three classes of drugs grew
substantially after the action. These knock-on effects weakened the capability of the price
adjustment action to control total pharmaceutical expenditures. This means that no saved
resources were available for other health care uses. Such expansion of pharmaceutical
consumption might also lead to inefficient use of the three drug classes: a large proportion of
patients obtained more than one day of drugs per day in the post-action period, suggesting
manipulation to increase reimbursement and offset price controls. We recommend that Taiwan's
government use the NHI data to establish a monitoring system to detect inappropriate prescription
patterns before implementing future policy changes. Such a monitoring system could then be used
to deter hospitals from abusing their prescription volumes, making it possible to more effectively
save health care resources by reducing drug reimbursement rates.
Background
Controlling the growth of pharmaceutical expenditures is
a major challenge all over the world [1-9]. Among various
methods for controlling pharmaceutical expenditures,
promotion of generic drug prescriptions or use has
received much support in recent years [6]. Such promo-
tion is usually through a mechanism of reference pricing
or mandatory generic substitution [6]. There are substan-
tial contextual differences in international experiences of
implementing pharmaceutical policies related to generic
drugs. Reporting experiences under different contexts can
inform future policy making.
To this date, there has been limited original research in
this area – presumably due to the difficulty in obtaining
good data. Most prior studies were conducted in advanced
Western countries. Almost all of them used macro-level or
aggregate data and most of them suffered difficulties of
disentangling the effects of policies concurrently applied
to control drug expenditures.
This study describes an experience of Taiwan, where
patients with chronic conditions are usually managed in
hospitals and drugs are provided in this setting with costs
reimbursed through the National Health Insurance
(NHI). It investigates the effects of Taiwan's reimburse-
ment rate adjustment based on chemical generic grouping
in 2001. This research also demonstrates the use of micro-
level data to generate policy-relevant information. This
can be used to improve efficiency of health care resource
use.
Taiwan started implementing its NHI in 1995. The Bureau
of National Health Insurance (BNHI) is the single buyer
in this universal public health insurance system. The
BNHI established a Pharmaceutical Benefit Scheme (PBS)
at the very beginning of the NHI, and since then it has
kept adjusting the content of the PBS based on the NHI
principles for drug reimbursement listing and pricing
[10,11].
The co-payment for drugs is low – with an upper limit of
200 Taiwanese dollars (about 6 US dollars) for each out-
patient visit and it is waived in most cases for outpatient
care. For instance, there is no co-payment for drugs curing
chronic conditions and patients with severe diseases
defined by the NHI are exempt from any co-payment for
drugs. On the other hand, Taiwan does not have a refer-
ence pricing system. The BNHI only reimburses for pre-
scription drugs listed in the PBS [10]. Patients using
resources in the NHI system cannot request drugs outside
the list by paying price differences.
The high proportion of NHI expenses on pharmaceuticals
has always been regarded as a problem in the system.
According to the BNHI's estimates, the proportion of NHI
expenses on pharmaceuticals was around 25% each year
from 1996 to 2002 and about 28% in 2003 [12]. The
BNHI uses the methods of positive listing, negative listing,
co-payment, and direct regulation for reimbursement
rates in order to keep pharmaceutical expenses under con-
trol [12]. Direct regulation for reimbursement rates is a
primary tool for the bureau to control pharmaceutical
spending. Such a strategy mainly targets hospitals as hos-
pital pharmaceuticals represent the primary part of total
pharmaceutical expenditures. For instance, in 2004,
around 80% of drug expenses for outpatient care wereBMC Public Health 2008, 8:118 http://www.biomedcentral.com/1471-2458/8/118
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through the hospital sector (estimates based on the NHI
research database).
All hospitals in Taiwan can offer outpatient care and have
on-site pharmacies. Patients visiting hospitals for outpa-
tient care directly acquire prescription drugs from those
hospitals [1]. Most clinics also have on-site pharmacies,
and physicians in such clinics prescribe as well as dispense
drugs [1]. For each outpatient visit in a clinic, if the pre-
scription duration does not exceed three days, the clinic
can use a simplified paperwork to claim a fixed daily
charge for the prescription. For outpatient visits with pre-
scriptions of a longer period, claiming drug reimburse-
ments requires paperwork for reporting the details of
drugs dispensed. Under this circumstance, physicians in
clinics are not interested in dispensing drugs for patients
whose prescriptions require the more complicated claim
procedure. Consequently, patients with chronic condi-
tions tend to obtain their prescription drugs in hospitals.
Any health care facility can make profit by dispensing pre-
scription drugs as long as its buying prices are lower than
the corresponding reimbursement rates [11]. When dis-
pensing drugs, health care facilities collect only co-pay-
ments from patients, and obtain the rest of drug charges
from the BNHI based on its reimbursement scheme and
the fee-for-services pattern. According to the law, the
bureau has to regularly adjust reimbursement rates to
achieve two goals [11]. The first goal is to reduce price dif-
ferences among drugs with identical ingredients, content,
volume, and dosage form without arousing arguments
over intellectual right or health care quality. The second is
to make reimbursement rates close to their corresponding
weighted average prices in the transaction markets
between pharmaceutical companies and health care facil-
ities contracting with the Bureau.
Regarding the first goal, since 2001, the bureau has used
the generic grouping method. Drugs with identical ingre-
dient, content, volume, and dosage form are categorized
as a group. Within each group, three types of drugs are
defined: (1) branded drugs from their original R&D com-
panies, (2) drugs with evidence on effectiveness from bio-
availability or bioequivalence studies (BA/BE generics),
and (3) generics other than BA/BE generics (common
generics) [13].
The BNHI prices branded drugs in reference to prices in
ten industrialized countries: UK, France, Germany, Swit-
zerland, Belgium, Sweden, USA, Canada, Australia, and
Japan. Branded drugs that have no local BA/BE generics to
compete with and new drugs under surveillance cannot be
priced over their corresponding median prices in the ten
countries. The other branded drugs cannot be priced over
85% of their corresponding median prices in the ten
countries.
The prices for BA/BE generics should not exceed 80% of
prices for their corresponding branded drugs. A BA/BE
generic that is being registered in the PBS for the first time
should not be priced higher than the lowest among prices
of existing BA/BE generics in the same group. The price of
a common generic should not exceed 80%of its corre-
sponding branded drug's price, and should not exceed the
lowest price of its corresponding BA/BE generics. For a
common generic that is being registered for the first time,
its price should be no more than the lowest price of exist-
ing common generics in the same group. Compared with
most other industrialized countries, Taiwan is generous in
pricing generic drugs. This pricing approach is used by the
BNHI to motivate health care facilities to dispense generic
drugs instead of branded drugs.
While the BNHI allows health care facilities to profit from
dispensing drugs, it tries to make drug reimbursement
rates close to their corresponding weighted average prices
in the transaction market between pharmaceutical com-
panies and health care facilities. For each reimbursement
rate adjustment action, the Bureau has to rely on informa-
tion from a drug market price survey administered to
pharmaceutical companies and health care facilities
before the action [11]. Pharmaceutical companies and
health care facilities cheating in such a survey have legal
responsibilities and face punishment from the Bureau, if
their frauds are uncovered.
For each drug, the Bureau calculates a weighted mean of
market prices using the corresponding transaction vol-
umes as the weights, and then adjusts its reimbursement
rate accordingly. Since 2001, there have been three large-
scale actions of reimbursement rate adjustments based on
chemical generic grouping and market price survey data.
They were implemented on April 1 of 2001, March 1 of
2003, and November 1 of 2006, respectively. The 2003
and 2006 actions were introduced under a global budget-
ing scheme for hospitals, while the 2001 action was not.
Presumably, reimbursement rate adjustment can produce
savings for the NHI, and subsequently the BNHI can use
the savings for other health services. However, NHI phar-
maceutical expenses continue to grow. A major driving
force for the growth is increased consumption of pharma-
ceuticals for treating chronic conditions. It has been
argued that Taiwan's expanding population with chronic
conditions is a major reason for the quickly increasing
consumption. Nevertheless, no research has empirically
explored whether any inefficiency in health care resource
use is associated with the quickly increasing consump-
tion. To shed light on this issue, this study investigatesBMC Public Health 2008, 8:118 http://www.biomedcentral.com/1471-2458/8/118
Page 4 of 13
(page number not for citation purposes)
potentially inefficient use of health care resources follow-
ing the reimbursement rate adjustment action in 2001.
We used micro-level NHI data to examine drug use before
and after the 2001 action. We selected this action in order
to focus on effects that directly result from reimbursement
rate adjustment, rather than effects mixing influences
from both reimbursement rate adjustment and global
budgeting. We chose the three most-used classes of cardi-
ovascular drugs based on the first four digits of the coding
system of Anatomical Therapeutic Classification (ATC).
They are beta blocking agents (ATC code = C07A; called
BBAs hereafter), calcium channel blockers mainly with
vascular effects (ATC code = C08C; called CCBs), and
plain ACE inhibitors (ATC code = C09A; called ACE-
inhibitors). In Taiwan, consumption on the three classes
accounts for over 50% of the total consumption of cardi-
ovascular drugs (our estimates based on NHI data). The
three classes were also among major classes targeted by
the 2001 action.
For each drug class, we examined changes in the daily
expense, number of days of the prescription, and total
expenditures for a pre-action period to a corresponding
post-action period. We used longitudinal data for a group
of patients who started using drugs of the class in the pre-
action period and continued to use such drugs in the post-
action period. Following changes in drug consumption
for such patients allowed us to investigate hospitals'
behaviour with respect to how they influence the irregu-
larly attending patients' drug use patterns after the action,
and generate policy-relevant information that can be used
to improve efficiency of health care resource use.
Methods
Study objectives
For each ATC class of drugs, this study aims to investigate
changes in the daily expense, the consumption volume,
and total expenditures from a six-month period before the
2001 action (the pre-action period) to a corresponding
six-month period after the action (the post-action period)
in the hospital setting. This study also intends to examine
whether any inappropriately high consumption of drugs
in the three classes existed.
Study periods and populations
The 2001 action was launched on April 1. We selected
"September 1,2000 to February 28, 2001" as the pre-
action period, and "September 1, 2001 to February 28,
2002" as the post-action period. We did not include the
first few months immediately following the action
because hospitals in such a period may not show their
"planned reactions with respect to the policy change" due
to their drug stocks or some of their valid contracts made
with pharmaceutical companies previously. The only pol-
icy difference between the two study periods was the
implementation of the 2001 action. Therefore, this study
does not have problems of disentangling effects from pol-
icies concurrently applied to control drug expenditures.
Each of Taiwan's generic grouping price adjustment
actions was implemented nation wide at the same time.
Therefore, we could not conduct a "before-and-after"
comparison with a control group by comparing "before-
and-after" changes across different places. Alternatively,
we compared an exposure group of patients who took
drugs targeted by the action, and a comparison group of
patients who took drugs not targeted by the action. If the
price of the drug a patient obtained from each outpatient
visit had a reduced price after the action, we included the
patient in the exposure group. If the price of the drug a
patient obtained from each outpatient visit was the same
or higher after the action, we included the patient in the
comparison group. The exposure group was substantially
more heavily influenced by the price adjustment than the
comparison group in terms of their daily expenses on
drugs.
Hypotheses
In Taiwan, the reimbursement rates for pharmaceuticals
covered by the NHI have always been set by the BNHI.
There is no variation in reimbursement rates across geo-
graphic locations or health care facilities, and all variation
across time is due to the BNHI reimbursement policy. For
patients in the exposure group, if their physicians did not
switch their prescription drugs to other, more expensive
drugs after the action, we should observe a reduction in
their daily drug expense. However, if their physicians
switched their drugs to other more expensive drugs, we
might observe no reduction in their daily drug expense.
We anticipated that the extent to which physicians could
switch their patients' drugs to other more expensive drugs
was limited, and thus hypothesized that we would
observe a reduction in the daily drug expense for the expo-
sure group. For the comparison group, the physicians had
no obvious reasons to switch the prescription drugs to less
expensive drugs. We thus hypothesized that we would
observe a non-downward trend in the daily drug expense
for this patient group.
Regarding consumption volume, we hypothesized that
physicians would increase the days of drug prescription
for both patient groups, since the NHI drug reimburse-
ment scheme has the fee-for-services pattern. We also
hypothesized that the total drug expenditure would
increase for both patient groups.
Unit of analysis
We constructed a longitudinal database for this study.
Each patient-hospital group in the database was treated asBMC Public Health 2008, 8:118 http://www.biomedcentral.com/1471-2458/8/118
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a cluster and contained two records – one for the pre-
action period and the other for the post-action period.
This allowed us to apply panel data estimation methods
to estimate the influences of the action.
Data sources
Our first data source is a longitudinal database for
200,000 individuals in Taiwan's National Health Insur-
ance Research Database. The 200,000 individuals are a
representative sample of Taiwan's NHI enrollees born in
year 2000 or earlier. We linked these data to correspond-
ing registration data of health care facilities in Taiwan and
an archive constructed by the BNHI to record all historical
data on the reimbursement rates of drugs covered by the
NHI.
For each ATC class of drugs, we then constructed a data file
consisting of records of outpatient visits made to hospitals
for treating hypertension for each aforementioned patient
group. Each record contained information about basic
characteristics of the hospital and of the patient, the date
of the visit, the major ICD 9 (International Classification
of Diseases, Ninth Revision) code for this visit, and the
prescription duration. Each record also contained infor-
mation on the name of prescription drug, its correspond-
ing type of price change (down, same, or up) caused by
the action, and the drug expense. Based on these visit
records, we further constructed a data file comprising
patient-hospital-period records. In other words, each
record pertained to a patient's use of pharmaceuticals
obtained from a specific hospital during the pre-action or
the post-action period. The process of constructing data
files for this study is described step-by-step in the appen-
dix.
Dependent and independent variables
The definitions of the three outcome variables for this
study are as follows: (1) Dayexp – drug expense per day
corresponding to a specific patient-hospital-period
record; (2) Totalday – the number of days of the drug pre-
scription corresponding to a specific patient-hospital-
period record; (3) Totalexp – the total drug expenditure
corresponding to a specific patient-hospital-period
record. The dependent variables are"the three outcome
variables in the form of the Napierian logarithm."Foreach
dependent variable, the explanatory variable is
"Post_Action." It was used to capture "the change in the
out come variable after the action."
We adopted the logarithm transformation for the out-
come variables in order to translate the relationship
between an outcome variable and its corresponding
explanatory variable into a measure of proportional
change [14]. This could facilitate comparisons across dif-
ferent drug classes and across different outcome variables.
Statistical model and empirical specification
We adopted the fixed effects linear regression model to
control for unobserved heterogeneity among patient-hos-
pital groups. The Huber/White/sandwich estimator was
employed to obtain robust variance estimates. This
method is a commonly used estimator of standard errors,
and it is robust without assuming that the standard errors
are independent from the explanatory variables and are
identically distributed [15]. We used the Stata Statistical
Software for our multivariate analysis.
Our empirical specification is as follows:
Yij = β0 + β1 Post_Actionij + αi + ε ij
The subscript "i" denotes the patient-hospital group, and
"j" denotes the period.
For each ATC class of drugs, we estimated separate equa-
tions for the exposure group and for the comparison
group. We then transformed the coefficient estimate for
"Post_Action" into a measure of proportional change, and
further calculated the 95% of confidence interval for the
proportional change. We compared the confidence inter-
vals between the exposure group and the comparison
group to make inferences regarding the influences of the
reimbursement rate adjustment action. We also pooled
data for both patient groups and estimated an equation
for the pooled sample. In this equation, we added an
interaction term with respect to the patient group and the
period (pre or post) to examine the difference between the
two patient groups.
Descriptive analysis regarding the number of days of 
prescription, the number of visits, and the number of drug 
items used
We applied descriptive statistics to depict the distribution
of the number of days of drug prescription, the number of
visits, and the number of drug items used for both patient
groups and for both pre- and post-action periods, respec-
tively. We calculated six selected percentiles for these three
measures: 25%, 50%, 75%, 95%, 99% and 100%. These
percentiles allowed us to investigate whether any inappro-
priate consumption of drugs in the three ATC classes
existed.
Sample characteristics
Table 1 summarizes the gender and age distributions of
our sample patients. No noticeable differences existed
between the two patient groups. We further investigated
the characteristics of outpatient visits separately for the
two patient groups. Generally speaking, no significant dif-
ferences existed between the two patient groups in terms
of hospital features (ownership, the profit-making type,
and the accreditation level), and the hypertension type.BMC Public Health 2008, 8:118 http://www.biomedcentral.com/1471-2458/8/118
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Nevertheless, for ACE-inhibitors, a significantly higher
percentage of visits were made to public hospitals for the
comparison group than for the exposure group. (Due to
the length, the characteristics of the outpatient visits were
not shown, but are available upon request.)
Results
The means of outcome variables
Table 2 summarizes the means of outcome variables for
the two patient groups and for the two periods, respec-
tively. The point estimates of the means show that the
daily expense significantly decreased for the exposure
group after the action, while such a trend was not
observed for the comparison group. Both consumption
volume (days of drugs prescribed) and total expenditures
significantly increased after the action for both patient
groups.
The effects on the daily drug expense
Table 3 indicates that daily drug expenses significantly
decreased from the pre-action period to the post-action
period for the exposure group. The average magnitudes of
decreases for BBAs, CCBs, and ACE-inhibitors were 14.8%
(= exp(-0.16)-1), 5.8% (= exp(-0.06)-1) and 5.8% (=
exp(-0.06)-1), respectively. In contrast, no reduction in
daily drug expenses from the pre- to the post-action
period was observed for the comparison group, and there
was even an increase of 3.1% (= exp(0.03)-1) for BBAs.
These results are consistent with our hypotheses.
For each ATC class of drugs, the 95% confidence interval
of proportional change reveals that change in daily drug
expenses from the pre- to the post-action period was sig-
nificantly different between the two patient groups. Our
estimation based on the pooled sample also yielded the
same findings (results not shown, but available upon
request).
The effects on the number of days of prescription
The results show a significant increase in the number of
days of drugs from the pre- to the post-action period for
each patient group (Table 4). Such results are consistent
with our hypotheses.
For the exposure group, the average magnitudes of
increases for BBAs, CCBs, and ACE-inhibitors were 76.8%,
68.2% and 64.9%, respectively. For the comparison
group, the average magnitudes of increases for the three
classes were 84.0%, 93.5% and 60.0%, respectively. We
found a substantial difference in the magnitude of change
between the two patient groups only for CCBs. For this
class of drugs, the magnitude of the increase was signifi-
cantly larger for the comparison group. Our estimation
based on the pooled sample reached the same conclu-
sions (results not shown).
The effects on total expenses
As hypothesized, total expenses significantly increased
after the action for both patient groups (Table 5). For the
exposure group, the average magnitudes of growth for
BBAs, CCBs, and ACE-inhibitors were 47.7%, 60.0% and
55.3%, respectively. For the comparison group, the aver-
age magnitudes for these three classes were 91.6%, 91.6%
and 63.2%, respectively. The size of increase was signifi-
cantly larger for the comparison group for both BBAs and
CCBs. However, no substantial difference in the size of
change emerged between the two patient groups for plain
Table 1: Characteristics of hypertension patients
Exposure group Comparison group
N% N %
Beta blocking agents
Number of patients 553 1064 511
Gender
Male 280 50.63 258 50.49
Female 273 49.37 253 49.51
Birth year
1960 or after 16 2.89 21 4.11
1940–1959 219 39.60 224 43.84
1920–1939 294 53.16 248 48.53
1919 or before 24 4.34 18 3.52
Calcium channel blockers, vascular effects
Number of patients 635 1202 567
Gender
Male 332 52.28 299 52.73
Female 303 47.72 268 47.27
Birth year
1960 or after 14 2.20 17 3.00
1940–1959 215 33.86 213 37.57
1920–1939 361 56.85 316 55.73
1919 or before 45 7.09 21 3.70
ACE inhibitors, plain
Number of patients 272 560 288
Gender
Male 155 56.99 179 62.15
Female 117 43.01 109 37.85
Birth year
1960 or after 9 3.31 10 3.47
1940–1959 112 41.18 92 31.94
1920–1939 132 48.53 169 58.68
1919 or before 19 6.99 17 5.90BMC Public Health 2008, 8:118 http://www.biomedcentral.com/1471-2458/8/118
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Table 2: Means of outcome variables
Pre-action Post-action Change after the action
mean std. dev. mean std. dev.
Exposure group
Beta blocking agents
Dayexp 11.77 6.79 9.94 6.00 -15.55%
Totalday 98.14 46.32 162.31 55.46 65.39%
Totalexp 1170.62 961.11 1632.12 1141.81 39.42%
Calcium channel blockers, vascular effects
Dayexp 21.67 7.59 20.21 6.84 -6.74%
Totalday 101.55 45.30 161.79 55.38 59.32%
Totalexp 2211.01 1293.61 3313.68 1641.13 49.87%
ACE inhibitors, plain
Dayexp 23.16 10.06 21.75 9.25 -6.09%
Totalday 100.21 48.50 154.67 58.88 54.35%
Totalexp 2341.01 1743.67 3374.22 2101.87 44.14%
Comparison group
Beta blocking agents
Dayexp 13.07 10.74 13.04 10.10 -0.23%
Totalday 95.03 48.30 160.27 55.68 68.65%
Totalexp 1287.80 1475.68 2117.25 1953.77 64.41%
Calcium channel blockers, vascular effects
Dayexp 20.49 6.77 20.23 6.70 -1.27%
Totalday 90.44 47.96 159.23 54.86 76.06%
Totalexp 1840.81 1171.14 3259.82 1641.34 77.09%
ACE inhibitors, plain
Dayexp 23.65 9.05 24.28 10.23 2.66%
Totalday 101.27 48.03 154.38 57.18 52.44%
Totalexp 2383.21 1539.46 3669.49 1994.09 53.97%
Table 3: Difference in the daily expense on drugs between the pre- and the post-action periods
Exposure group Comparison group
Coefficient 95% CI of change measured in % Coefficient 95% CI of change measured in %
Beta blocking agents
Post_Action -0.16** (-17, -12) 0.03† (0, 5)
Test Statistic F (1,552) = 105.97** F (1,510) = 3.36†
# observations 1106 1022
# patient-hospital groups 553 511
Calcium channel blockers, vascular effects
Post_Action -0.06** (-8, -4) -0.02 (-4, 0)
Test Statistic F (1,634) = 26.44** F (1,566) = 2.49
# observations 1270 1134
# patient-hospital groups 635 567
ACE inhibitors, plain
Post_Action -0.06** (-9, -2) 0.01 (-1, 4)
Test Statistic F (1,271) = 10.69** F (1,287) = 0.95
# observations 544 576
# patient-hospital groups 272 288
** p < 0.01; * p < 0.05; † p < 0.1.BMC Public Health 2008, 8:118 http://www.biomedcentral.com/1471-2458/8/118
Page 8 of 13
(page number not for citation purposes)
ACE inhibitor. We had the same inferences based on esti-
mation using the pooled sample (results not shown).
The distribution of the number of days of prescription, the 
number of visits, and the number of drug items used
Table 6 reports the 25th, the 50th, the 75th, 95th, 99th and
the 100th percentiles for the number of days of drugs, the
number of visits, and the number of drug items used. The
number of days of drugs prescribed and the number of
visits also increased grew considerably after the action. In
contrast, changes in the number of drug items were not
significant.
Approximately 50% of patients' consumption in the post-
action period escalated to a level of longer than 180 days
of prescription drugs belonging to a specific ATC class for
a six-month period. On the other hand, this expansion of
pharmaceutical use raised the consumption level of low-
volume users in the pre-action period closer to the
required level of daily treatment for hypertension after the
action.
Discussion
In Taiwan, patients with chronic conditions do not have
to be very cost-conscious for prescription drugs due to the
low co-payment policy and because physicians tradition-
Table 4: Difference in the number of days of prescription drugs between the pre- and the post-action periods
Exposure group Comparison group
Coefficient 95% CI of change measured in % Coefficient 95% CI of change measured in %
Beta blocking agents
Post_Action 0.57** (68, 86) 0.61** (73, 95)
Test Statistic F (1,552) = 459.97** F (1,510) = 378.21**
# observations 1106 1022
# patient-hospital groups 553 511
Calcium channel blockers, vascular effects
Post_Action 0.52** (60, 76) 0.66** (83, 106)
Test Statistic F (1,634) = 418.20** F (1,566) = 518.10**
# observations 1270 1134
# patient-hospital groups 635 567
ACE inhibitors, plain
Post_Action 0.50** (52, 78) 0.47** (49, 73)
Test Statistic F (1,271) = 154.52** F (1,287) = 150.38**
# observations 544 576
# patient-hospital groups 272 288
** p < 0.01; * p < 0.05; † p < 0.1.
Table 5: Difference in the total expenditure on drugs between the pre- and the post-action periods
Exposure group Comparison group
Coefficient 95% CI of change measured in % Coefficient 95% CI of change measured in %
Beta blocking agents
Post_Action 0.39** (38, 58) 0.65** (78, 106)
Test Statistic F (1,552) = 131.54** F (1,510) = 316.63**
# observations 1106 1022
# patient-hospital groups 553 511
Calcium channel blockers, vascular effects
Post_Action 0.47** (50, 69) 0.65** (80, 105)
Test Statistic F (1,634) = 237.32** F (1,566) = 371.13**
# observations 1270 1134
# patient-hospital groups 635 567
ACE inhibitors, plain
Post_Action 0.44** (42, 70) 0.49** (51, 78)
Test Statistic F (1,271) = 95.05** F (1,287) = 139.76**
# observations 544 576
# patient-hospital groups 272 288
** p < 0.01; * p < 0.05; † p < 0.1.BMC Public Health 2008, 8:118 http://www.biomedcentral.com/1471-2458/8/118
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Table 6: Selected percentiles of the number of days of drugs, of the number of visits, and of the number of drug items
Exposure group Comparison group
Pre-action Post-action Pre-action Post-action
Beta blocking agents
The number of days of drugs
25% 60 120 56 120
50% 92 180 90 170
75% 140 210 140 210
95% 168 224 168 228
99% 180 252 196 249
100% 210 280 224 300
The number of visits
25% 2 4 2 4
50% 4 7 4 6
75% 5 7 5 7
95% 6 8 6 8
99% 10 11 8 10
100% 13 14 23 24
The number drug items
25% 1 1 1 1
50% 1 1 1 1
75% 1 1 1 1
95% 1 2 1 2
99% 2 2 2 3
1 0 0 % 3324
Calcium channel blockers, vascular effects
The number of days of drugs
25% 60 120 56 120
50% 112 180 90 180
75% 140 210 133 198
95% 168 224 168 225
99% 180 264 182 240
100% 196 330 224 300
The number of visits
25% 3 5 2 4
50% 4 6 3 6
75% 5 7 5 7
95% 6 8 6 8
99% 12 13 9 11
100% 30 27 12 13
The number drug items
25% 1 1 1 1
50% 1 1 1 1
75% 1 1 1 1
95% 2 2 1 1
99% 2 2 1 2
1 0 0 % 4323
ACE inhibitors, plain
The number of days of drugs
25% 60 112 60 112
50% 112 168 104 168
75% 140 202 140 203
95% 168 224 172 224
99% 180 249 196 240BMC Public Health 2008, 8:118 http://www.biomedcentral.com/1471-2458/8/118
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ally make decisions on pharmaceutical use for patients.
Therefore, the effects of drug reimbursement rate adjust-
ment depend on hospital administrators' and physicians'
reactions. This study did not found evidence that hospi-
tals in Taiwan prescribed more expensive drugs to an
extent that the policy aim of reducing pharmaceutical unit
price was invalid. However, hospitals significantly
expanded volumes of prescription drugs for their regularly
attending patients after the action. Consequently, total
expenditures on the three most-used classes of cardiovas-
cular drugs for such patients dramatically increased.
While the exposure group tended to have a smaller growth
rate for total expenditures than the comparison group, the
large increases in consumption for the three classes of
drugs certainly deserve more attention and scrutiny.
Another issue deserving more exploration is that this
expansion of pharmaceutical consumption might also
lead to inefficient use of the three drug classes, as a large
proportion of patients obtained more than one day of pre-
scription drugs belonging to a specific class per day in the
post-action period.
Hospitals appeared to ask their patients to return to the
hospitals to acquire prescription drugs more frequently.
Hospitals in Taiwan usually arrange future visits for their
patients, so it is possible that hospitals manipulate time
intervals between consecutive visits for their regularly
attending patients to expand the volumes of drugs dis-
pensed. Our additional analysis of the number of drug
items used for patients obtaining different numbers of
days of prescription drugs does not provide evidence that
hospitals use "prescribing different drugs in the same class
in different out patient visits" as a strategy to be able to
dispense more than one day of drugs belonging to a spe-
cific class per day and avoid being found fraudulent by the
BNHI. To dispense more drugs, hospitals simply increased
the number of visits.
Hypertension patients taking medicine more regularly
appeared to be a major driver of the growth in expendi-
tures on the three classes of drugs. When we estimated
aggregate expenditures on the three drug classes using
NHI data for all patients rather than only the sample
patients for this study, we found a much lower growth rate
of pharmaceutical expenses for each drug class (results not
shown). This implies that hospitals targeted patients more
regularly taking medicine to expand their revenues from
dispensing drugs.
Another issue deserving more attention is that the
decrease magnitude of the daily expense found by this
study (14.8% for BBAs, 5.8% for CCBs, 5.8% for ACE-
inhibitors) was lower than the average level of price reduc-
tion for the drugs with reduced prices (16.7% for BBAs,
12.9% for CCBs, 11.4% for ACE-inhibitors – as shown in
Table 7). Probably, our sample patients tended to be those
taking drugs with smaller price reductions. Another possi-
ble explanation for this is that some patients' prescription
drugs were switched to more expensive drugs after the
action.
The literature has had only one original research article
reporting Taiwan's experience of implementing the
generic grouping price policy [12]. This study was based
on monthly data of total NHI pharmaceutical expendi-
tures, and used the time-series data intervention analysis
method. This paper concludes that the generic grouping
price policy shifted the trend of total NHI pharmaceutical
expenses, and was helpful for saving health care costs.
Nevertheless, data reported in that paper also show that
total NHI pharmaceutical expenses kept growing after a
significant reduction immediately following the 2001
action. As a result, total expenditures at the end of 2001
were higher than the amount at the end of 2000. There-
fore, our findings do not contradict their results.
100% 224 288 240 245
The number of visits
25% 2 4 2 4
50% 4 6 4 6
75% 5 7 5 7
95% 7 9 7 9
9 9 % 1 21 41 21 3
100% 30 27 12 14
The number drug items
25% 1 1 1 1
50% 1 1 1 1
75% 1 1 1 1
95% 1 2 1 1
99% 2 3 2 2
1 0 0 % 3322
Table 6: Selected percentiles of the number of days of drugs, of the number of visits, and of the number of drug items (Continued)BMC Public Health 2008, 8:118 http://www.biomedcentral.com/1471-2458/8/118
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For other Asian countries with health care systems more
similar to Taiwan's, we have not found any original arti-
cles reporting their experiences. Some Western countries
have experiences related to Taiwan's in respect to reference
pricing or mandatory generic substitution. The literature
shows mixed results regarding international experiences
in reference pricing. Evidence has indicated that reference
pricing saved pharmaceutical expenses on angiotension-
converting enzyme (ACE) inhibitors and calcium channel
blockers in Canada [16], but did not effectively contain
public pharmaceutical expenditure for Germany and
Spain [17,18]. In Hungary, therapeutic reference pricing
increased the average defined daily dose per prescription
and expenditure on statins [19]. In contrast, Sweden's
experience in mandatory generic substitution policy
appears promising, as this policy has produced savings for
both the patients and society [20]. In many western coun-
tries, in addition to physicians' reactions, the effects of
their policies of pricing pharmaceuticals are related to the
behavioural changes of pharmacists and patients. In Tai-
wan, hospital administrators and physicians are main
players in reacting to governmental pharmaceutical poli-
cies, and pharmacists and patients have negligible roles.
Therefore, we cannot directly compare results from this
study with those found in these western countries. Never-
theless, experiences in these western countries and Taiwan
all make it clear that only relying on a reference pricing
system or a generic grouping reimbursement policy can-
not effectively control pharmaceutical expenditures.
One primary problem in Taiwan's healthcare sector is that
the government has not been able to separate drug pre-
scription and dispensation [1,21]. In Taiwan, physicians
have stronger political power than pharmacists and
patients. Making profit from dispensing prescription
drugs is also traditionally acceptable in the health care sec-
tor. Such a tradition originated mainly from a strategy to
earn physicians' political support in the period when
Japan governed Taiwan and has been kept since [21]. It is
a major obstacle to separate drug prescription and dispen-
sation. Moreover, since the NHI payment system is still
under much criticism and controversy, the government
allows hospitals differentiate between the drug reimburse-
ment rates and hospitals' corresponding purchasing prices
as their profits [21]. This certainly gives hospitals incen-
tives to expand the volumes of drugs dispensed and makes
it difficult to control pharmaceutical expenditures.
It is certainly politically difficult to fundamentally reform
the prescription and dispensation system and the NHI
payment scheme in the near future. In the short run, how-
ever, the government can construct a monitoring system
for studying health care providers' behaviours by taking
advantage of the individual longitudinal database that
was originally built for handling NHI reimbursements. In
Taiwan, the government can always make policies and the
non-governmental sectors targeted by these policies can
subsequently formulate strategies to make these policies
ineffective. To design effective and appropriate policies for
controlling health care expenditures, it is necessary to con-
duct in-depth research regarding health care providers'
reactive behaviours for different policy changes.
Micro-level longitudinal data of reliable quality and with
sufficient information are necessary for doing good
research in this regard. In the least, there should be infor-
mation regarding health care providers' characteristics
and individual patients' demographic background, mor-
bidity conditions and health care utilization. The govern-
ment could devote more efforts to construct such
databases to help researchers conduct more rigorous pol-
icy evaluations to generate relevant information for pre-
venting inefficient use of health care resources. In
particular, countries with public health insurance should
Table 7: Reimbursement rate changes from the pre- to the post-action period
Beta blocking agents
Number of all kinds covered by the NHI in the pre- or the post-action period 170
Number of kinds with price reduction after the action 65
% of kinds with price reduction after the action 38.24%
The average level of price reduction (%) of those with reduced prices 16.67%
Calcium channel blockers, vascular effects
Number of all kinds covered by the NHI in the pre- or the post-action period 74
Number of kinds with price reduction after the action 48
% of kinds with price reduction after the action 64.86%
The average level of price reduction (%) of those with reduced prices 12.87%
ACE inhibitors, plain
Number of all kinds covered by the NHI in the pre- or the post-action period 95
Number of kinds with price reduction after the action 50
% of kinds with price reduction after the action 52.63%
The average level of price reduction (%) of those with reduced prices 11.36%BMC Public Health 2008, 8:118 http://www.biomedcentral.com/1471-2458/8/118
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utilize administrative data for reimbursement purposes to
construct an information system to enhance their capabil-
ity of managing health care resource allocation.
This paper has provided a preliminary example of the use
of micro-level longitudinal data to uncover inappropriate
consumption of drugs. For resource management pur-
poses, it would be even more helpful to trace changes in
hospitals' patterns of prescribing and dispensing pharma-
ceuticals, including their choices within narrow therapeu-
tic classes and volumes of drugs dispensed for different
narrow therapeutic classes. Such a tracing system can
make it possible to effectively save health care resources
and then use saved resources for other health services.
Building a model for such a tracing system based on the
NHI research database is a major line of our future
research. Investigating the relationships of hospitals' pat-
terns of prescribing and dispensing pharmaceuticals with
their characteristics is also a direction of our future
research. Further more, we plan to explore whether physi-
cians' behaviour of switching drugs for treating a specific
disease affects their patients' use of other health care
related to the disease. Since we are not able to acquire data
about hospitals' purchasing prices for pharmaceuticals,
we cannot directly examine how the amount of profit
from dispensing drugs influences hospitals' decision mak-
ing with respect to drug choices across as well as within
narrow therapeutic classes, and volumes of prescription
drugs they dispense for different drug classes. This is the
major limitation in our research.
Conclusion
The 2001 price adjustment action, based on generic
grouping, significantly reduced the daily expense on each
of the three classes of cardiovascular drugs. However, in
response to this policy change, hospitals in Taiwan tended
to greatly expand the volume of drugs prescribed for their
regularly attending patients. Consequently, the total
expenditures for the three classes of drugs grew substan-
tially after the action. These knock-on effects weakened
the price adjustment action's capability of controlling
total pharmaceutical expenditures. This means that no
saved resources were available for other health care uses.
Such expansion of pharmaceutical consumption might
also lead to inefficient use of the three drug classes: a large
proportion of patients ended up obtaining more than one
day of prescription drugs per day in the post-action
period. This suggests manipulation to increase reimburse-
ment and offset price controls. We recommend that Tai-
wan's government use the NHI data to establish a
monitoring system to detect inappropriate prescription
patterns before implementing future policy changes. Such
a monitoring system could then be used to deter hospitals
from abusing their prescription volumes, making it possi-
ble to more effectively save health care resources by reduc-
tions in drug reimbursement rates.
Appendix
The process of constructing the data files for this study
This appendix describes the step-by-step process of con-
structing the analytical data files. Detailed results gener-
ated from each step are not included, but available upon
request.
Step 1
We identified outpatient visits based on the following cri-
teria, for each ATC class of drugs:
1. those made by all hypertension patients in the NHI
database of 200,000 enrolees.
2. those made in the pre- or the post-action periods (the
pre-action period: 2000/09/01 to 2001/02/28; the post-
action period: 2001/09/01 to 2002/2/28).
3. those with a major ICD code of 401–405.
4. those with a prescription including the specific ATC
type of drug.
Step 2
We retained data of those visits that included prescrip-
tions of only one drug belonging to the ATC class.
(Almost all visits belonged to this type.) This was done to
simplify the analysis without losing essential data for
making inferences.
Step 3
1. For each visit, we combined information regarding the
patient identification number and the hospital identifica-
tion number to create a group identification (ID) number
(These numbers were scrambled so that the real identity of
the patient was kept confidential).
2. We defined four types of visits with: (1) a patient-hos-
pital group ID number appearing in both the pre- and the
post-action periods for individuals with only 1 ID; (2) a
patient-hospital group ID number appearing in both the
pre- and the post-policy periods for individuals with more
than 1 ID; (3) a patient-hospital group ID number appear-
ing only in the pre-action period; (4) a patient-hospital
group ID number appearing only in the post-action
period. Individuals paying type 3 or type 4 visits used the
drug only in either the pre- or the post-action periods, or
they switched hospitals after the action. This study focuses
on how hospitals reacted to the action by influencing theirBMC Public Health 2008, 8:118 http://www.biomedcentral.com/1471-2458/8/118
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regular patients' drug usage; therefore, analysis with
respect to the last two types of patients was not conducted.
Step 4
1. We removed data of type 3 and 4 visits for the purpose
of comparing outcomes between the two periods for each
patient-hospital group.
2. We kept only data of type 1 visits for the sake of simpli-
fying the analysis without losing essential data for making
inferences (Almost all visits belonged to this type).
Step 5
We removed data of the individuals who did not belong
to the exposure or the comparison group, and data of
those who had missing variables (The percentages of visits
dropped after this step ranged from 8 to 9%. The percent-
ages of patients dropped after this step ranged from 13 to
16%).
Step 6
We constructed the following data files for this study.
(1) Data file 1 (for beta blocking agents, patient-hospital-
period records): Number of observations = 2128 (number
of total patient-hospital groups × 2: one for the pre-action
period, and one for the post-action period).
(2) Data file 2 (for calcium channel blockers mainly with
vascular effects, patient-hospital-period records): Number
of observations = 2404.
(3) Data file 3 (for plain ACE inhibitors, patient-hospital-
period records): Number of observations = 1120.
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